View in EDS

Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.

Saved in:
Bibliographic Details
Title: Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.
Authors: Bates EA; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Davies JA; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Váňová J; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.; Department of Genetics and Microbiology, Faculty of Science, Charles University, Viničná 5, 128 44 Prague 2, Czech Republic., Nestić D; Division of Molecular Biology, Ruđer Bošković Institute, Bijenička cesta 54, 10000 Zagreb, Croatia., Meniel VS; European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK., Koushyar S; European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK., Cunliffe TG; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Mundy RM; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Moses E; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Uusi-Kerttula HK; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Baker AT; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Cole DK; Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Majhen D; Division of Molecular Biology, Ruđer Bošković Institute, Bijenička cesta 54, 10000 Zagreb, Croatia., Rizkallah PJ; Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Phesse T; European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK., Chester JD; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.; Velindre Cancer Centre, Whitchurch, Cardiff CF14 2TL, UK., Parker AL; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.
Source: Molecular therapy oncolytics [Mol Ther Oncolytics] 2022 Mar 16; Vol. 25, pp. 43-56. Date of Electronic Publication: 2022 Mar 16 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101666776 Publication Model: eCollection Cited Medium: Print ISSN: 2372-7705 (Print) Linking ISSN: 23727705 NLM ISO Abbreviation: Mol Ther Oncolytics Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2372-7705
DOI:10.1016/j.omto.2022.03.007